Shuncong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuncong Zhang has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Kai Yuan
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
8 shared publicationsWei Deng
The First Clinical Academy, Guangzhou University of Chinese Medicine, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510407, China; Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
6 shared publicationsHuizhi Guo
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
5 shared publicationsYongchao Tang
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
5 shared publicationsGuoye Mo
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
4 shared publications- Liangliang Xu
Lingnan Medical Research Center, The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine
4 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1871132
An exploratory multimodal imaging and clinicopathological strategy for suspected Kümmell’s disease in the absence of MRI
Background: Diagnosing Kümmell’s disease (KD) remains a clinical challenge when patients present with contraindications for magnetic resonance imaging (MRI). To address this issue, we propose and make a preliminary attempt at a promising exploratory multimodal diagnostic strategy. It directly combines structural imaging with metabolic data for KD when MRI is contraindicated. Materials and methods: We evaluated suspected KD patients using a stepwise workflow. Following initial clinical symptom screening, patients underwent plain radiography and high-resolution computed tomography (CT) to detect key morphological signs, such as intervertebral vacuum clefts (IVCs) and fracture-end sclerosis. Finally, we utilized 99 ᵐTc-MDP bone scintigraphy, namely emission computed tomography (ECT), to assess the actual metabolic status of the affected vertebrae. Results: CT scans provided conclusive anatomical evidence of vertebral injury and instability. ECT scans revealed metabolic activity, identifying lesions with high metabolic activity (hot areas) or decreased radiotracer uptake intensity (cold areas), corresponding to repair processes and avascular necrosis, respectively. The combination of these multimodal examinations provided convergent imaging evidence supportive of the diagnosis of KD. Conclusion: For KD patients who are not suitable for MRI, a combination of CT and ECT bone imaging may serve as a feasible exploratory diagnostic approach. This technique may help address some limitations of single-modality assessment by linking anatomical information with metabolic activity, contributing to more accurate diagnosis and more informed clinical decision-making.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1871132
Open AccessAn exploratory multimodal imaging and clinicopathological strategy for suspected Kümmell’s disease in the absence of MRI
Background: Diagnosing Kümmell’s disease (KD) remains a clinical challenge when patients present with contraindications for magnetic resonance imaging (MRI). To address this issue, we propose and make a preliminary attempt at a promising exploratory multimodal diagnostic strategy. It directly combines structural imaging with metabolic data for KD when MRI is contraindicated. Materials and methods: We evaluated suspected KD patients using a stepwise workflow. Following initial clinical symptom screening, patients underwent plain radiography and high-resolution computed tomography (CT) to detect key morphological signs, such as intervertebral vacuum clefts (IVCs) and fracture-end sclerosis. Finally, we utilized 99 ᵐTc-MDP bone scintigraphy, namely emission computed tomography (ECT), to assess the actual metabolic status of the affected vertebrae. Results: CT scans provided conclusive anatomical evidence of vertebral injury and instability. ECT scans revealed metabolic activity, identifying lesions with high metabolic activity (hot areas) or decreased radiotracer uptake intensity (cold areas), corresponding to repair processes and avascular necrosis, respectively. The combination of these multimodal examinations provided convergent imaging evidence supportive of the diagnosis of KD. Conclusion: For KD patients who are not suitable for MRI, a combination of CT and ECT bone imaging may serve as a feasible exploratory diagnostic approach. This technique may help address some limitations of single-modality assessment by linking anatomical information with metabolic activity, contributing to more accurate diagnosis and more informed clinical decision-making.
- 13 August 2025
- Published by Springer Nature in Biogerontology
- Vol. 26 (5) , 162
Cytoskeleton-associated protein 4: a double-edged sword in cell growth and aging
Cytoskeleton-Associated Protein 4 (CKAP4) is a multifunctional protein implicated in diverse cellular processes, including cytoskeletal organization, signal transduction, and extracellular matrix remodeling. Recent studies have highlighted the dual role of CKAP4 in regulating cell growth and aging. On one hand, CKAP4 can promote cell proliferation and survival by activating signaling pathways such as PI3K/Akt, thereby delaying cellular senescence under physiological conditions. On the other hand, under chronic stress or pathological stimuli, CKAP4 may induce cell cycle arrest and accelerate aging by interacting with ligands such as antiproliferative factor (APF) and Dickkopf-1 (DKK1), leading to the upregulation of cell cycle inhibitors and the suppression of autophagy. Moreover, CKAP4 has emerged as a key mediator linking extracellular matrix remodeling to inflammatory responses, which are closely associated with age-related diseases. This review comprehensively summarizes the current understanding of CKAP4's molecular mechanisms in cell longevity and aging, discusses its involvement in inflammation and tissue homeostasis, and explores its potential as a therapeutic target for aging-related disorders.
- 13 August 2025
- Published by Springer Nature in Biogerontology
- Vol. 26 (5) , 162
Cytoskeleton-associated protein 4: a double-edged sword in cell growth and aging
Cytoskeleton-Associated Protein 4 (CKAP4) is a multifunctional protein implicated in diverse cellular processes, including cytoskeletal organization, signal transduction, and extracellular matrix remodeling. Recent studies have highlighted the dual role of CKAP4 in regulating cell growth and aging. On one hand, CKAP4 can promote cell proliferation and survival by activating signaling pathways such as PI3K/Akt, thereby delaying cellular senescence under physiological conditions. On the other hand, under chronic stress or pathological stimuli, CKAP4 may induce cell cycle arrest and accelerate aging by interacting with ligands such as antiproliferative factor (APF) and Dickkopf-1 (DKK1), leading to the upregulation of cell cycle inhibitors and the suppression of autophagy. Moreover, CKAP4 has emerged as a key mediator linking extracellular matrix remodeling to inflammatory responses, which are closely associated with age-related diseases. This review comprehensively summarizes the current understanding of CKAP4's molecular mechanisms in cell longevity and aging, discusses its involvement in inflammation and tissue homeostasis, and explores its potential as a therapeutic target for aging-related disorders.
- 22 January 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (1) , 90-101
Buqi-Tongluo Decoction inhibits osteoclastogenesis and alleviates bone loss in ovariectomized rats by attenuating NFATc1, MAPK, NF-κB signaling
- 22 January 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (1) , 90-101
Buqi-Tongluo Decoction inhibits osteoclastogenesis and alleviates bone loss in ovariectomized rats by attenuating NFATc1, MAPK, NF-κB signaling
- Open Access
- 5 December 2024
- Published by Elsevier in World Neurosurgery
- Vol. 194, 123439-10
The Correlation Analysis Between the Pedicle Screw Placement Palpation and Torque
- 5 December 2024
- Published by Elsevier in World Neurosurgery
- Vol. 194, 123439-10
Open AccessThe Correlation Analysis Between the Pedicle Screw Placement Palpation and Torque
- Open Access
- 19 January 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 171, 116166
Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function
- 19 January 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 171, 116166
Open AccessCorylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function
- Open Access
- 15 September 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117166
Panax notoginseng saponins inhibits oxidative stress- induced human nucleus pulposus cell apoptosis and delays disc degeneration in vivo and in vitro
- 15 September 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117166
Open AccessPanax notoginseng saponins inhibits oxidative stress- induced human nucleus pulposus cell apoptosis and delays disc degeneration in vivo and in vitro
- Open Access
- 13 March 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 211, 115502
Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK
- 13 March 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 211, 115502
Open AccessIsoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK
- 26 February 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 210, 115463
Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding
- 26 February 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 210, 115463
Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding
- Open Access
- 21 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1015693
Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity
Background: Osteoporosis is a type of systematic metabolic bone disease caused by the decrease in osteogenic activity or excessive resorption of bone with the relative enhancement of osteoclast function. As osteoporosis seriously affects the quality of patients’ life, effective drugs are needed to treat this disease. Based on the combination of network pharmacology and cellular studies, this study aimed to investigate the probable mechanism of Dehydromiltirone (DHT) in the treatment of osteoporosis.Method: The targets of DHT in osteoporosis were searched using the PharmGKB, OMIM, and Genecard platforms. The PPI core targets, and the GO and KEGG enrichment analysis results were obtained using Cytoscape software, and the David and Metascape databases, respectively. The network pharmacology results were also verified via in vitro cellular experiments.Results: Through network pharmacology and docking analysis, we found DHT was involved in peptide tyrosine phosphorylation, cell surface receptor tyrosine kinase signaling pathways, and MAPK signaling pathways. According to the molecular docking results, the binding of DHT to MAPK14 was more stable than other proteins, which suggests that DHT may affect osteoclast formation through the MAPK signaling pathway. Moreover, DHT was found to inhibit the expression of osteoclast-associated genes, including NFATc1, CTSK, c-Fos, Acp5, and MMP9; as well as the phosphorylation of P38, ERK, and JNK of the MAPK signaling pathway; and the degradation of IκB-α of NF-κB signaling pathway.Conclusion: DHT exhibited an anti-osteoclastogenesis effect by reducing the expression of related genes, ultimately inhibiting bone resorption in vitro.
- 21 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1015693
Open AccessDehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity
Background: Osteoporosis is a type of systematic metabolic bone disease caused by the decrease in osteogenic activity or excessive resorption of bone with the relative enhancement of osteoclast function. As osteoporosis seriously affects the quality of patients’ life, effective drugs are needed to treat this disease. Based on the combination of network pharmacology and cellular studies, this study aimed to investigate the probable mechanism of Dehydromiltirone (DHT) in the treatment of osteoporosis.Method: The targets of DHT in osteoporosis were searched using the PharmGKB, OMIM, and Genecard platforms. The PPI core targets, and the GO and KEGG enrichment analysis results were obtained using Cytoscape software, and the David and Metascape databases, respectively. The network pharmacology results were also verified via in vitro cellular experiments.Results: Through network pharmacology and docking analysis, we found DHT was involved in peptide tyrosine phosphorylation, cell surface receptor tyrosine kinase signaling pathways, and MAPK signaling pathways. According to the molecular docking results, the binding of DHT to MAPK14 was more stable than other proteins, which suggests that DHT may affect osteoclast formation through the MAPK signaling pathway. Moreover, DHT was found to inhibit the expression of osteoclast-associated genes, including NFATc1, CTSK, c-Fos, Acp5, and MMP9; as well as the phosphorylation of P38, ERK, and JNK of the MAPK signaling pathway; and the degradation of IκB-α of NF-κB signaling pathway.Conclusion: DHT exhibited an anti-osteoclastogenesis effect by reducing the expression of related genes, ultimately inhibiting bone resorption in vitro.
- 28 July 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (3) , 1950-1966
Carnosol suppresses RANKL‐induced osteoclastogenesis and attenuates titanium particles‐induced osteolysis
Osteolysis is a common medical condition characterized by excessive activity of osteoclasts and bone resorption, leading to severe poor quality of life. It is essential to identify the medications that can effectively suppress the excessive differentiation and function of osteoclasts to prevent and reduce the osteolytic conditions. It has been reported that Carnosol (Car), isolated from rosemary and salvia, has anti‐inflammatory, antioxidative, and anticancer effects, but its activity on osteolysis has not been determined. In this study, we found that Car has a strong inhibitory effect on the receptor activator of nuclear factor‐κB ligand (RANKL)‐induced osteoclast differentiation dose‐dependently without any observable cytotoxicity. Moreover, Car can inhibit the RANKL‐induced osteoclastogenesis and resorptive function via suppressing NFATc1, which is a result of affecting MAPK, NF‐κB and Ca2+ signaling pathways. Moreover, the particle‐induced osteolysis mouse model confirmed that Car could be effective for the treatment of bone loss in vivo. Taken together, by suppressing the formation and function of RANKL‐induced osteoclast, Car, may be a therapeutic supplementary in the prevention or the treatment of osteolysis.
- 28 July 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (3) , 1950-1966
Carnosol suppresses RANKL‐induced osteoclastogenesis and attenuates titanium particles‐induced osteolysis
Osteolysis is a common medical condition characterized by excessive activity of osteoclasts and bone resorption, leading to severe poor quality of life. It is essential to identify the medications that can effectively suppress the excessive differentiation and function of osteoclasts to prevent and reduce the osteolytic conditions. It has been reported that Carnosol (Car), isolated from rosemary and salvia, has anti‐inflammatory, antioxidative, and anticancer effects, but its activity on osteolysis has not been determined. In this study, we found that Car has a strong inhibitory effect on the receptor activator of nuclear factor‐κB ligand (RANKL)‐induced osteoclast differentiation dose‐dependently without any observable cytotoxicity. Moreover, Car can inhibit the RANKL‐induced osteoclastogenesis and resorptive function via suppressing NFATc1, which is a result of affecting MAPK, NF‐κB and Ca2+ signaling pathways. Moreover, the particle‐induced osteolysis mouse model confirmed that Car could be effective for the treatment of bone loss in vivo. Taken together, by suppressing the formation and function of RANKL‐induced osteoclast, Car, may be a therapeutic supplementary in the prevention or the treatment of osteolysis.